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Summary. It has been shown that computerized algorithms
for the prescription of coumarin derivates can improve the
quality of long-term anticoagulation treatment. These
algorithms are usually based on an empiric relationship
between dosage and International Normalized Ratio and do
not quantify the delaying eﬀect of the drug’s pharmaco-
kinetics or the eﬀect of alternating doses that are used to
approximate a certain average dosage. Our objective was to
develop a mathematical model that takes into account these
eﬀects and to develop a new algorithm based on this model
that can be used to further optimize the quality of long-
term anticoagulation treatment. We simpliﬁed a general
model structure that was proposed by Holford in 1986 so
that the parameters can be estimated using data that are
available during long-term anticoagulation treatment. The
constant parameters in the model were estimated separately
for phenprocoumon and acenocoumarol using data from
1279 treatment courses from three diﬀerent anticoagulation
clinics in the Netherlands. The only variable parameter in
the model is the sensitivity of the patient, which is estimated
during the course of each treatment. A total of 194 dosage
and appointment intervals that were proposed by the new
algorithm were scored as good, acceptable, or bad by
two dosing experts. One hundred and seventy-eight (91.8%)
proposals were considered good by at least one expert and
bad by none. In 39 cases the experts disagreed. We believe
that this algorithm will allow further improvement of
anticoagulation treatments.
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Introduction
Oral anticoagulant therapy with coumarin derivatives is used
for a variety of indications such as mechanical heart valve
prostheses, deep vein thrombosis and atrial ﬁbrillation [1].
Inadequate treatment with these drugs increases the risk of
thromboembolic (under-anticoagulation) and bleeding (over-
anticoagulation) complications [2]. Therefore, the intensity of
anticoagulation is regularly monitored by assessment of the
International Normalized Ratio (INR) and the INR is kept as
much as possible within a predeﬁned target range. In the
Netherlands the monitoring of the INR is handled by
approximately 70 anticoagulation clinics. Patients on antico-
agulation therapy visit these clinics every 1–6 weeks to have
their INR measured and to receive a new calendar with daily
dose prescriptions by mail 1 day later (dose calendar).
Acenocoumarol (Sintrom mitis) and phenprocoumon
(Marcoumar) are the licensed coumarin derivates.
If the measured INR is outside the predeﬁned target range
the dosage needs to be adapted. Determining the new dosage is
complicated by several factors. First, the sensitivity of patients
to the drug is subject to a pronounced inter-individual and, in
the course of time, intra-individual variability. Second, because
of the inﬂuence of delaying processes such as pharmacokinet-
ics, and the complex relationship between dose and INR, it is
difﬁcult to make accurate dose adjustments. Third, the INR
shows ﬂuctuations that are unpredictable andmay be the result
of differential sensitivity of the thromboplastin reagent used [3],
and unknown variations in diet, medication, compliance or
physical condition of the patient.
To facilitate anticoagulation dosing, several computerized
algorithms have been developed in the past and have been
shown to improve the quality of control [4–8]. In the Nether-
lands several anticoagulation clinics use an algorithm called
TRODIS that was ﬁrst developed in 1973 [9]. TRODIS uses a
complex empiric decision-tree that determines whether the
dosagehas tobeadaptedand, if it has,whetheranewdosagecan
be calculated by the algorithm (dosage proposal) or whether it
has to be determined by the physician. In practice, TRODIS
only proposes a dosage in approximately 60% of all cases,
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25% of which are subsequently overruled by the physicians
upon review. In the case that a new dosage has to be calculated,
TRODIS uses a simple dose–INR relationship that calculates
the new dosage based on the INR and previous dosage only.
Thisapproachhasseveralweaknesses.First, itdoesnot take into
account the pharmacokinetics of the drug or the effect of
previousdosageadjustments.Second,TRODISdoesnotuse the
actual daily doses that are prescribed on the last visit’s dose
calendarbut the average.On the calendar, for instance, apatient
receives instructions to alternately take two and one tablets per
day, which TRODIS uses as a dosage of 1.5 tablets per day.
Especially for acenocoumarol with its short half-life of 24 h [10]
it is relevant to know how many (in this instance either one or
two)pillswereprescribed to thepatient thedaybefore thevisit to
the anticoagulation clinic. Finally, after the previous visit the
dosing physician may have decided to either prescribe an extra
loading dose if the INR was too far below target, or stop the
dosing for one ormore days if the INRwas too far above target
(stop-dose). These actions are not taken into account if the
algorithm only uses the average dosage instead of using the
actual prescriptions on the dose calendar.
In conclusion, TRODIS only makes use of a subset of all the
information that is available to adjust the dosage. The
anticoagulation process is simply too complex to derive an
empiric relationship between all the available data and the right
dosage that will yield an INR near the target at the next visit.
A common approach in engineering to control complicated
systems is to develop a mathematical model that describes the
effect of the input on the output. An algorithm that is based on
such a model controls the output (INR) by choosing the input
(dosage) that yields the desired output (target INR), as
predicted by the mathematical model. In the case of compu-
terized anticoagulation dosing it may be expected that an
algorithm that uses such a mathematical model will lead to
faster andmore accurate corrections of the dosage. This in turn
will lead to a higher percentage of time-in-range, and fewer
visits to the anticoagulation clinic per year. A fewmathematical
models with this purpose have already been developed, but
they either use input that is not available during the therapy,
such as individual levels of clotting factors, or they only operate
during the initiation of therapy [11–14].
This article describes three steps that were taken to develop
an algorithm for the prescription of oral anticoagulants. First a
model structure for the above mentioned mathematical model
is determined. Second, the parameters of the model are
optimized to data from three anticoagulation clinics in the
Netherlands. Finally the algorithm is evaluated by two
physicians who are expert at prescribing anticoagulation
dosages at the anticoagulation clinic in Leiden.
Methods
Data
We imported data from the computerized databases of the
anticoagulation clinics of Leiden, Utrecht and The Hague into
a relational database. Data were related to one of three entities:
patients, treatments and visits. For each patient we obtained
both date of birth and sex. For each treatment course we
imported the date of onset, indication and, if applicable, the
end date of treatment. For each visit we collected the date of
visit, the result of the INRmeasurement, the dose calendar, the
target INR and recorded remarks from the physicians and
nurses. The remarks are coded and can contain information
about co-medication, initial doses and about loading or stop-
doses.
We selected treatment courses that complied with the
following inclusion criteria. Onset of treatment on or after 1
January 1994 (anticoagulation clinics in Leiden andUtrecht) or
on or after 1 January 1997 (The Hague), and before 1 January
2000. The time span of each treatment course was restricted to
one of the following end-points: recorded end of a treatment
course, admission to hospital, or 1 January 2000. Only
treatment courses with phenprocoumon or acenocoumarol as
the prescribed anticoagulant were selected. Treatment courses
with a shift of anticoagulant from phenprocoumon to
acenocoumarol or vice versa were excluded. Treatment courses
with INR targets other than 3.0 (range 2.5–3.5) or 3.5 (range
3.0–4.0) (the commonly used INR targets in the Netherlands
during the time window of this study) were also excluded. To
make parameter estimation possible, only treatment courses
where patients did not use coumarins prior to their entry in the
database of the anticoagulation clinic andwhere the initial dose
(the dose between onset of treatment and ﬁrst visit to the
anticoagulation clinic) was available in the database were
included. Each patient may have undergone several non-
overlapping treatment courses, with each treatment course
comprising one or more visits.
Mathematical model
To develop a mathematical model that can be ﬁtted to the
available data we took the general model structure that was
presented in 1986byHolford as a startingpoint [15]. Thismodel
comprises four submodels, which are explained below (Fig. 1a).
The ﬁrst submodel describes the pharmacokinetics of the oral
anticoagulant. This submodel gives the plasma concentration of
theanticoagulantagentasa resultof thedrug intake.Thesecond
submodel characterizes the direct relationship between the
plasma concentration of the anticoagulant and the production
rateof vitaminK-dependent clotting factors.This relationship is
also referred to as the pharmacodynamic relationship. The third
submodeldescribes the relationshipbetween theproductionrate
ofvitaminK-dependentclotting factorsand the resulting levelof
these factors, expressed as the activity of the prothrombin
complex. Finally, the fourth submodel represents the relation-
ship between the prothrombin complex activity and the
measured INR.
Note that the ﬁrst and third submodels together describe the
delay on the effect of the anticoagulant. The parameters of
these models are the half-life of the drug and the half-lives of
the clotting factors.
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Estimation of all variables of the four submodels is difﬁcult
in a practical setting, because:
1 only the INR is measured, so the plasma level of the
anticoagulant and the prothrombin complex activity have
to be inferred,
2 the time span between subsequent visits is variable and
relatively long compared to typical clotting factor half-lives
of approximately 12 h [16].
To overcome these difﬁculties, we simpliﬁed the structure of
the model by combining the ﬁrst and third submodels into one
submodel, and the second and fourth submodels into another,
thus obtaining a newmodel structure with only two submodels,
referred to in the following text as the Improved Control of
Anticoagulation Dosage (ICAD) model (Fig. 1b).
In the ICAD model, the ﬁrst submodel describes the
collective inﬂuence of all delaying processes, whereas the
second submodel describes the relationship between the dosage
and the corresponding INR. So instead of using the prescribed
dosage directly as an input to the dose–effect relationship, it is
ﬁrst corrected for delays. We call this corrected dosage the
eﬀective dose. Imagine starting a prescription of a drug at two
pills per day. If the half-life of the drug equals 1 day, then the
eﬀect of the drug after 1 day will be the equivalent of an
average dose of one pill per day, whereas after two days the
effect will be the equivalent of 1.5 pills per day. Only after
several days will the effect of the average dosage (or the
effective dose) approximate the effect of a long-term treatment
of two pills per day. The only parameter of this ﬁrst submodel
is the half-life of the effect (t½)which is approximately the same
as the half-life of the drug.
Recall that the second submodel of the ICAD model is a
direct cascade of Holford’s second and fourth submodels. For
Holford’s pharmacodynamic submodel we adapted a sigmoid
E-max model [16], thus:
pðtÞ ¼
f c1=2
f c1=2 þ fðtÞc
ð1Þ
where p(t) represents the production rate of vitamin-K
dependent clotting factors and f(t) represents the dose, and
where the two parameters f½ and c determine the position and
shape of the sigmoid curve. The measured INR depends on the
level of the clotting factors, but also varies because of the
differential sensitivity to the used thromboplastin reagent.
Because during normal therapy these quantities are unknown,
and because the thromboplastin reagent batch was not
imported in the database, we assumed a simple hyperbolic
relationship between the prothrombin complex activity (PCA)
and the INR, such that:
INRðtÞ ¼ aþ b
PCAðtÞ ð2Þ
where PCA(t) is the relative prothrombin complex activity
(between 0 and 1) and a and b are two parameters. Per
deﬁnition a prothrombin complex activity of 100% (PCA ¼ 1)
corresponds to an INR that equals 1 which implies that
a+b ¼ 1. Cascading equations (1) and (2) with p ¼ PCA
yields the following effective dose–INR relationship:
INRðtÞ ¼ 1þ s  ðfðtÞÞc ð3Þ
in which we introduced the parameter s¼b/f1/2c called the
sensitivity of the patient.
Parameter estimation
Up to this point, the only unknown parameters in the model
are the sensitivity of the patient s (eqn 3), the effective half-life
of the anticoagulant t½ (ﬁrst submodel) and the E-max
parameter c (eqn 3). We assumed t½ and c to be attributes of
the anticoagulant and therefore constant during the treatment.
The sensitivity s is patient-dependent and assumed to be
variable during the treatment. Therefore, s needs to be
calculated during the course of the treatment, while the other
two parameters can be optimized with retrospective data.
With each new visit to the anticoagulation clinic a new
sensitivity follows from eqn 3, the measured INR and the
calculated effective dose. Because the prescribed dose calendar
is stored in the database the effective dose at the next visit can
also be calculated. Using eqn 3 again, the effective dose
together with the sensitivity can then be used to predict the
INR at the next visit. Depending on how accurate the model is
there will be a difference between the predicted INR and the
measured INR. This difference is known because the measured
INR at the next visit is also stored in the database and it can be
calculated for each visit (except the ﬁrst one) and for all
treatments. These differences can thus be used as a measure of
accuracy for the model. The parameters c and t½ can
subsequently be optimized by minimizing these differences.
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Fig. 1. (a) General model structure consisting of four submodels for the relation between dose and INR (Holford’s model). (b) Lumping linear
dynamics and static non-linearities in two separate submodels yields the simpliﬁed ICAD model structure.
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This means that the parameters are varied until the differences
are minimal. This is done using a computer program and a
minimization criterion, which is described in theAppendix. The
resulting set of parameters are then said to be optimized
because the mathematical model gives the best predictions with
these parameters.
For each anticoagulant (phenprocoumon and acenocouma-
rol) we randomly assigned all treatment courses to a derivation
and validation data set (half–half). The derivation data were
used for optimizing the parameters by using a Nelder–Mead
simplex (direct search) method. Comparison of the minimiza-
tion criteria in both data sets was used to assess whether the
model would yield a comparable accuracy in an independent
data set.
With all the parameters known, the model can be used in an
algorithm to determine which dosage would result in an INR
equal to the target. This maintenance dose should equal the
effective dose in eqn 3 such that the INR equals the target:
d ¼ INR
target  1
s
 1=c
ð4Þ
where d equals the dosage proposal, INRtarget equals the target
INR and s equals the sensitivity.
It is known that the INR shows random variations that are
not related to prolonged changes in the sensitivity to the
coumarin derivate. These random variations will affect the
calculated sensitivity at each visit and would subsequently have
an effect on the prescribed dosage. In the algorithm therefore,
the calculated sensitivity is averaged with previously calculated
values. The weight of these values decreases exponentially in
time [17,18]. Figure 2 shows the resulting ﬂow diagram that is
used in the algorithm.
The algorithm is furthermore tolerant for small variations in
the sensitivity (no dosage change) and puts a limit on the
maximumallowable dosage change (either positive or negative).
Thechange insensitivity since the lastvisit to theanticoagulation
clinic can be regarded as a measure of patient stability. The
algorithm uses this value to calculate a new appointment
period by applying a simple empiric relationship. TheAppendix
gives a short overview of the most important equations.
Expert evaluation
To assess whether the dosage proposals and appointment
periods calculated by the algorithm are acceptable, prior to
designing a study to clinically test the algorithm, 95 visits for
acenocoumarol and 99 visits for phenprocoumon were ran-
domly selected from the total number of included visits. The
algorithm was used to generate dosage proposals for these
selected visits. These proposals were independently analyzed by
two physicians who are experts in dosing oral anticoagulation
at the anticoagulation clinic in Leiden. The proposals were
scored according to a three-point system. One point was
assigned to dosage proposals and appointment periods that
were in complete agreement with the expert opinion (good),
2 points were assigned to proposals that were marked
acceptable, which meant that the expert would have pre-
scribed by himself or herself a slightly different dosage
prescription or appointment period (the ICAD dosage propo-
sal was, however, considered sufﬁciently safe to be accepted),
3 points were given if the dosage proposal or appointment
period was different from the expert opinion in such a way that
a serious under or over dosage was to be expected (unaccept-
able). Afterwards, the database was used to determine for
which cases TRODIS made a dosage proposal in the past. The
proposals made by TRODIS were not evaluated.
Results
Parameter estimation
From the computerized databases of the three anticoagulation
clinics we imported 23 481 treatment courses (14 917 treatment
courses with acenocoumarol and 8564 treatment courses with
phenprocoumon) that fell within the speciﬁed time span. These
sensitivity
dose calendar
delay
correction 
with half-
life
(t½) 
dose-effect 
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INR
exponential
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inverse
dose-effect 
relationship
target
INR
effective dose
sensitivity
dosage suggestion
Fig. 2. Flow diagram showing the most important steps the algorithm
takes to calculate a new dosage suggestion (bottom) from the measured
INR and prescribed dose calendar (top). First the dose calendar is used
to calculate the eﬀective dose at the time of the visit, using the eﬀective
half-life parameter t½. Together with the measured INR, the eﬀective
dosage is used to calculate the sensitivity of the patient. This sensitivity is
averaged with previous measured sensitivities using exponentially
decreasing weight factors. The averaged sensitivity is then used to calculate
a new dosage suggestion from the target INR by applying the inverse
dose–eﬀect relationship.
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treatment courses comprised a total of 322 262 recorded visits
(198 636 with acenocoumarol and 123 626 with phenprocou-
mon). From these data 1279 treatment courses (16 314 visits)
with acenocoumarol and 937 treatment courses (12 997 visits)
with phenprocoumon complied with our inclusion criteria.
Most treatments were excluded because the patient used
coumarins before the start of the treatment, or because the
initial dose at the onset of treatment had not been correctly
stored in the database and was not available.
Table 1 shows the characteristics for these treatment courses
using the data stored in the database. From the total of 1279
treatment courses with acenocoumarol, 640 were assigned to a
validation set, whereas 639 were assigned to a derivation set.
From the total of 937 treatment courses with phenprocoumon
469 were assigned to a phenprocoumon validation set, whereas
468 were assigned to a derivation set. The parameters t½ and c
that were estimated with the derivation data sets are presented
in Table 2. For acenocoumarol an effective half-life of
2.08 days with a standard error (SE) of 0.08 days was found,
whereas for phenprocoumon an effective half-life of 8.35 days
(SE 0.15) was found. The estimate of parameter c was 2.37
(SE 0.10) for acenocoumarol and 2.71 (SE 0.07) for phenpro-
coumon. When we compared the minimized criteria of the
derivation data sets with the criteria of the validation data sets
it became clear that the model performed similarly on an
independent set of data.
Expert evaluation
The 194 dosages and appointment periods proposed by the
ICAD algorithm were independently analyzed by two experts.
Table 3 shows the results. One hundred and seventy-eight
(91.8%) ICAD proposals were considered good by at least
one expert and bad by none. In 183 cases (94.3%) the
proposal was qualiﬁed either good or acceptable by both
experts. In 39 cases the experts disagreed: in 28 cases one
expert qualiﬁed the ICAD proposal as good while the other
qualiﬁed it as average, in six cases the proposal was qualiﬁed
as good as well as bad and in ﬁve cases as acceptable and
bad. In 61 of the 150 (77.3%) cases in which the ICAD
proposal was qualiﬁed as good by both experts, TRODIS was
not able to present a proposal.
Discussion
A simpliﬁed model with a reduced set of parameters was
derived from Holford’s theoretical model structure, and this
model could be used to calculate dosage proposals for the
physician. Using data from three anticoagulation clinics we
optimized the parameters of themodel for both acenocoumarol
and phenprocoumon, while a similar procedure can be used to
estimate parameters for other coumarin derivatives, such as
warfarin. Finally, evaluations by two experts showed a high
acceptance of the dosage and appointment period proposals of
the algorithm.
Several earlier studies have modeled pharmacodynamics
using a sigmoid E-max model. Although these studies use
warfarin as the anticoagulant agent, the estimation of the
E-Max parameter c largely complies with our ﬁndings [19,20].
The ﬁrst ICAD submodel describes the inﬂuence of all dynamic
processes that determine the time-dependent relationship
between dose and INR. Because pharmacokinetics is known
to be of major inﬂuence, we expected the effective half-life to be
at least as long as the half-life of the anticoagulant agent. The
half-lives of acenocoumarol and phenprocoumon are, respect-
ively, 24 h and 160 h, whereas we found longer effective
half-lives of 50 and 200 h. It is likely that the difference of
Table 1 Characteristics of included treatment courses
Anticoagulant
Acenocoumarol Phenprocoumon
No. of treatments 1279 937
(No. of visits) (16 314) (12 997)
Male (%) 47 51
Average age (years) at
onset of treatment
57 58
Average no. of visits 12.8 13.9
Average visit interval (days) 13.3 16.4
INR target range 2.5–3.5 3.0–4.0 2.5–3.5 3.0–4.0
No. of treatments 1141 138 808 129
(No. of visits) (13 502) (2812) (9854) (3143)
Average INR 2.67 3.15 2.92 3.33
SD (1.24) (1.28) (1.10) (1.27)
Table 2 Results for the parameter estimation. Upper part of table shows
the results of optimizing parameters c and t½ for both acenocoumarol and
phenprocoumon and the resulting minimization criterion for both the
derivation and validation data sets
Anticoagulant
Acenocoumarol Phenprocoumon
c (SE) 2.37 (0.10) 2.71 (0.07)
t½ (SE) days 2.08 (0.08) 8.35 (0.15)
Minimization criterion
in derivation set
0.673 0.443
Minimization criterion
in validation set
0.666 0.442
Table 3 Results of the expert evaluation
Total score dose/
appointment
proposal
Anticoagulant
Total (%)
Acenocoumarol
(%)
Phenprocoumon
(%)
2 75 (78.9%) 75 (75.8%) 150 (77.3%)
3 13 (13.7%) 15 (15.2%) 28 (14.4%)
4 (two acceptable
scores)
1 (1.1%) 4 (4.0%) 5 (2.6%)
Total of above 89 (93.7%) 94 (94.9%) 183 (94.3%)
4 (one bad,
one good)
4 (4.2%) 2 (2.0%) 6 (3.1%)
5 2 (2.1%) 3 (3.0%) 5 (2.6%)
6 0 0 0
Total of all 95 (49%) 99 (51%) 194 (100%)
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approximately 1.6 days can be attributed to the remaining
processes that have a time-dependent and delaying inﬂuence.
Based on data from six anticoagulation clinics, it has recently
been shown that the variability in control of treatments with
acenocoumarol is higher compared to that with phenpro-
coumon [21,22]. This could explainwhywith phenprocoumona
longer mean visit interval is found compared to treatment
courseswith acenocoumarol (13.3 days vs. 16.4 days), although
the mean INR is closer to the center of the INR target range.
A combination of several factors makes it difﬁcult for the
dosing physician to determine a reliable new dosage. These are
variability of the patient’s sensitivity, the delay in the effect of
the anticoagulant, the variability in the prescribed doses and
the unpredictable variations in the measured INR. TRODIS
uses an empiric dose–INR relationship that does not take into
account the above-mentioned factors and the dose–INR
relationship is chosen to be steep so that proposed dosage
corrections are relatively small. As a result, TRODIS reacts
slowly to changes in the sensitivity to the drug which leads to
lower time-in-range. TRODIS resembles other algorithms that
are described in literature like Coventry, Hillingdon and
DAWN AC in a sense that they combine a decision tree or
table with an empiric dose–INR relationship [5,7,10,23,24].
One drawback of the model-based strategy that we followed
is that the quality of the dosage proposals is limited by the
accuracy of the underlying mathematical model. In this study,
the parameters were ﬁtted using a large amount of historical
data, but the equations themselves remain theoretical. A better
model could be derived if not only the prescribed doses and
measured INR were known, but also intermediate variables
like the plasma level of the anticoagulant and the level of
individual clotting factors. However, these measurements were
not present in the available data of the anticoagulation clinics
and are not used in daily practice, in which clotting factor
measurements are not routinely carried out.
Another important drawback of the model-based approach
is that the model is ﬁtted on historic data and there is no
guarantee that the inverse path, calculating the necessary
dosage from the target INR, yields accurate dose prescriptions.
Although the expert evaluation gives an indication of the
quality of the dosage proposals, it cannot be used as a gold
standard, because we expect that the new algorithm will yield
better controlled anticoagulation therapies than those that are
currently achieved by the physicians and TRODIS.
An important advantage is that improvements to the
mathematical model can easily be incorporated into the
algorithm. The model could, for example, be enhanced with
more input variables like individual clotting factors or the
sensitivity of the thromboplastin reagent.
The next step will therefore be to start a randomized
controlled trial that compares the new algorithm against
TRODIS. The expert evaluation shows that the dosage and
appointment periods proposed by the algorithm were highly
acceptable by the two experts, which makes such a randomized
trial feasible and justiﬁed. We hope that a model-based and
more quantitative approach to the prescription of oral
anticoagulants, as proposed in this study, will lead to safer
and more effective anticoagulation therapies.
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Appendix
Minimization criterion
The INRby deﬁnition is a ratio between two quantities and has
a theoretical lower bound of 1. Therefore it is mathematically
more correct to use the natural logarithm of the ratio of the
predicted INR and measured INR, both corrected for the
lower bound, as a measure of accuracy. The root mean square
of this quantity was taken as the minimization criterion:
J ¼
ﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃ
log
INRpredicted  1
INRmeasured  1
 2vuut ð5Þ
The ICAD algorithm
The dose calendars with daily drug doses are used to calculate
the effective dose up to the last day of the treatment course
using the following formula:
fnþ1 ¼ k  fn þ ð1 kÞ  dn ð6Þ
with fn the effective dose at day n and dn the dose that was taken
at day n according to the dose calendar. The parameter k
corresponds to the relative decrease per day of the effective
dose. It can also be expressed as the number of days that
corresponds to a decrease of 50%, which yields the more
intuitive effective half-time: t½ ¼ (log ½)/(log k) (in days).
Because only treatment courses were included where onset of
treatment by the anticoagulation clinic also means initiation of
anticoagulation therapy it is known a priori that the initial
effective dose is zero ( f0 ¼ 0).
After the kth visit to the coagulation clinic the effective dose is
combined with themeasured INR to yield a ﬁrst estimate of the
sensitivity:
sk ¼ INRk  1
f ck
ð7Þ
with sk the sensitivity at visit k, INRk the measured INR at visit
k, and fk the calculated effective dose at visit k.
This sensitivity is averaged with previous sensitivities using
exponential weighting. Themaintenance dose can subsequently
be calculated from equation 4.
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